OCUP News and Press, Ocuphire Pharma Inc Com From 03/08/22

With Growing Rate of Childhood Myopia, MIRA-4 Trial Supports a Potential Broader RM Label for Nyxol in Pediatric Subjects 3 to 11 Years Ocuphire Delivering on Execution Early in 2022, Momentum Builds with Completion of Patient Enrollment in 3 Late-Stage Trials for Nyxol Up...

Ocuphire Pharma (OCUP +3.4%) announced an earlier-than-expected completion in the recruitment of its second Phase 3 registration trial for Nyxol eye drops, which is designed to assess the alpha-1 blocker in the reversal of pharmacologically induced mydriasis (RM). Topline data from the study ...

Gainers: Haemonetics (NYSE:HAE) +13%. Second Sight Medical Products (NASDAQ:EYES) +8%. Catalyst Pharmaceuticals (NASDAQ:CPRX) +6%. Quotient (NASDAQ:QTNT) +5%. Ocuphire Pharma (NASDAQ:OCUP) +3%. Losers: Pulse Biosciences (NASDAQ:PLSE) -36%. Karyopharm Th...

Completed enrollment ahead of schedule in second Phase 3 FDA registration trial for Nyxol in RM (MIRA-3) with top-line results expected soon around the end of 1Q22 VEGA-1 Phase 2 data showing the efficacy of Nyxol as a single-agent eye drop and together with low-dose pilocarpine...

New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients enrolled New masked data show favorable safety profile for oral APX3330 ...

Update on Late-Stage Clinical Trials in the APX3330 and Nyxol Programs as well as Commercial Insights for Nyxol for RM and Presbyopia by Six Leading KOLs Webinar to Take Place on Monday, January 31 st @ 10am ET FARMINGTON HILLS, Mich., Jan. 25, 2022 (GLOBE NEWS...

Completed Enrollment of Nyxol ® LYNX-1 Phase 3 NVD Trial Initiated Enrollment of Nyxol MIRA-4 Pediatric Study in RM per Agreed Initial Pediatric Study Plan with FDA Nyxol MIRA-3 Phase 3 Results, MIRA-4 Pediatric Results, and LYNX-1 Phase 3 Results Expected i...

FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has ap...

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Ocuphire Pharma, Inc. Announces Enrollment of First Patients in the MIRA-3 Phase 3 pivotal trial” Ocuphire Pharma, Inc. (NASDAQ: OCUP) surged over 44% ...

Shares of Ocuphire Pharm (OCUP +36.2%) have jumped today after H.C. Wainwright initiated the stock with a buy rating and $26 price target (647% upside). Analyst Matthew Caufield writes that the company is benefitting from top-line phase 3 data of Nyxol (phentolamine) in reversing mydrias...